MLICM
VKTX icon

Metropolitan Life Insurance Company (MetLife)’s Viking Therapeutics VKTX Stock Holding History

Metropolitan Life Insurance Company (MetLife)’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-5,377
Closed -$441K – 2043
2024
Q1 		$441K Sell
5,377
-176
-3% -$7.83K 0.02% 496
2023
Q4 		$103K Hold
5,553
– – ﹤0.01% 1062
2023
Q3 		$61.5K Buy
5,553
+299
+6% +$4.28K ﹤0.01% 1282
2023
Q2 		$85.2K Buy
+5,254
New +$110K ﹤0.01% 1106
2022
Q2 		– Sell
-4,757
Closed -$14.3K – 2436
2022
Q1 		$14.3K Sell
4,757
-10,542
-69% -$37.8K ﹤0.01% 2217
2021
Q4 		$70.4K Sell
15,299
-2,780
-15% -$15.6K ﹤0.01% 2636
2021
Q3 		$114K Sell
18,079
-1,039
-5% -$6.42K ﹤0.01% 2460
2021
Q2 		$115K Sell
19,118
-1,331
-7% -$7.9K ﹤0.01% 2723
2021
Q1 		$129K Buy
20,449
+11,354
+125% +$79.9K ﹤0.01% 2307
2020
Q4 		$51.2K Sell
9,095
-5,173
-36% -$31.3K ﹤0.01% 2475
2020
Q3 		$83K Sell
14,268
-7,409
-34% -$51K ﹤0.01% 2321
2020
Q2 		$156K Sell
21,677
-80
-0.4% -$531 ﹤0.01% 1977
2020
Q1 		$102K Buy
21,757
+1,108
+5% +$6.81K ﹤0.01% 2017
2019
Q4 		$166K Sell
20,649
-507
-2% -$3.7K ﹤0.01% 2045
2019
Q3 		$146K Hold
21,156
– – ﹤0.01% 2092
2019
Q2 		$176K Buy
21,156
+1,028
+5% +$8.78K ﹤0.01% 1975
2019
Q1 		$200K Sell
20,128
-1,794
-8% -$15K ﹤0.01% 1899
2018
Q4 		$168K Buy
21,922
+6,599
+43% +$78.9K ﹤0.01% 1934
2018
Q3 		$267K Hold
15,323
– – ﹤0.01% 1812
2018
Q2 		$145K Buy
+15,323
New +$102K ﹤0.01% 2131

Other funds holding VKTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Pictet Asset Management
Pictet Asset Management Carouge, Switzerland $105B AUM 38.07% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Metropolitan Life Insurance Company (MetLife)'s VKTX Position: Q2 2024 in Review

Metropolitan Life Insurance Company (MetLife) sold out of Viking Therapeutics (VKTX) in Q2 2024, closing a stake of 5,377 shares — an estimated $441K sold.

Metropolitan Life Insurance Company (MetLife) first reported a position in VKTX in Q2 2018 and held it in 20 quarters. The position peaked at $441K in Q1 2024. 387 funds tracked by Wall St. Rank hold VKTX as of Q2 2024.

  • Metropolitan Life Insurance Company (MetLife) reported no remaining Viking Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Metropolitan Life Insurance Company (MetLife) sold 5,377 Viking Therapeutics shares in Q2 2024, an estimated $441K.
  • Metropolitan Life Insurance Company (MetLife) first reported a position in Viking Therapeutics in Q2 2018 and held it in 20 quarters.
  • Metropolitan Life Insurance Company (MetLife)'s Viking Therapeutics position peaked at $441K in Q1 2024.
  • 387 funds tracked by Wall St. Rank held Viking Therapeutics as of Q2 2024.

Based on Metropolitan Life Insurance Company (MetLife)'s 13F filing for Q2 2024, filed 13 Aug 2024.